Haystack Oncology

Haystack Oncology, based in Baltimore, Maryland, is a biotechnology company focused on developing innovative cancer diagnostics. The company employs 55 individuals and generates approximately $50 million in annual revenue. Haystack Oncology is dedicated to improving patient outcomes through its groundbreaking technology. Haystack Oncology's flagship product, Haystack MRD™, is a cutting-edge minimal residual disease (MRD) test. This test utilizes next-generation sequencing to detect minute traces of circulating tumor DNA (ctDNA) in patients' blood, providing valuable insights into the presence of residual disease after cancer treatment. What sets Haystack MRD apart is its tumor-informed approach. Leveraging over two decades of research and expertise from Johns Hopkins University, the test is designed to deliver highly precise results, enabling clinicians to make more informed treatment decisions. This personalized approach has the potential to significantly impact patient care and improve long-term survival rates. For more information about Haystack Oncology and its innovative MRD testing solutions, please visit their website at haystackmrd.com.